Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity

J Fla Med Assoc. 1992 Dec;79(12):821-2.

Abstract

A case is reported of reversible sensorineural hearing loss associated with intravenous erythromycin treatment. Cis-platinum induced high frequency hearing loss developed nine months previously during treatment for stage IV papillary cystadenocarcinoma. Renal and hepatic function were normal; however, serum erythromycin levels were elevated. Clinical recovery promptly followed discontinuation of erythromycin.

Publication types

  • Case Reports

MeSH terms

  • Cisplatin / adverse effects*
  • Cystadenocarcinoma / drug therapy
  • Erythromycin / administration & dosage
  • Erythromycin / adverse effects*
  • Erythromycin / blood
  • Female
  • Hearing Loss, High-Frequency / chemically induced*
  • Hearing Loss, Sensorineural / chemically induced*
  • Humans
  • Injections, Intravenous
  • Middle Aged
  • Ovarian Neoplasms / drug therapy

Substances

  • Erythromycin
  • Cisplatin